CO191 Clinical Effectiveness and Cost-Analysis of New Oral Antidiabetics in a Cohort of Type 2 Diabetic Patients from a Cardiovascular Risk Program in Colombia
The objective was to analyze clinical outcomes and costs of patients in the year before and after the new medication was introduced. (Source: Value in Health)
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: E. Echeverri, Á.J. Ruiz, M. Rondon, S. Echeverri, D. Rosselli Source Type: research
EPH58 Adverse Events Associated with Sodium Glucose Co-Transporter-2 Inhibitors: A Pharmacoepidemiologic Analysis Using FAERS Database 2012-2022
Sodium Glucose Co-Transporter-2 (SGLT2) inhibitors canagliflozin, dapagliflozin, and empagliflozin are commonly used for type 2 diabetes mellitus treatment. The FDA warns of serious adverse events (AEs) related to the use of SGLT2 inhibitors, such as limb amputations, kidney injury and ketoacidosis (Source: Value in Health)
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: M. Gari, M. Alrasheed, J.J. Guo Source Type: research
EE7 The Importance of Considering Price Metrics and Market Dynamics in US Economic Evaluations: The Case of Sglt-2 Inhibitors in the Treatment of Type 2 Diabetes (T2D)
In the US T2D market, prices reflect both branded and generic competition, within and across classes. Despite recommendations, comparative economic analyses usually hold relative prices constant and, equally unrealistic, often use list prices. Even the few analyses that use prices net of manufacturer rebates understate opportunity costs by excluding time-varying intermediary margins. We illustrate the implications of these choices by simulating canagliflozin 300mg vs. sitagliptin 100mg in treating T2D. (Source: Value in Health)
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: M. Willis, C. Neslusan, A. Nilsson Source Type: research
Canagliflozin mitigates carfilzomib-induced endothelial apoptosis via an AMPK-dependent pathway
In conclusion, our findings demonstrate for the first time the direct toxic effects of CFZ in endothelial cells and the associated signaling changes. Canagliflozin abrogated the apoptotic effects of CFZ in endothelial cells in an AMPK-dependent mechanism, without interfering with its cytotoxicity in cancer cells.PMID:37247463 | DOI:10.1016/j.biopha.2023.114907 (Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie)
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - May 29, 2023 Category: Drugs & Pharmacology Authors: Mohamed S Dabour Ibrahim Y Abdelgawad Marianne K O Grant Engie S El-Sawaf Beshay N Zordoky Source Type: research
Canagliflozin mitigates carfilzomib-induced endothelial apoptosis via an AMPK-dependent pathway
In conclusion, our findings demonstrate for the first time the direct toxic effects of CFZ in endothelial cells and the associated signaling changes. Canagliflozin abrogated the apoptotic effects of CFZ in endothelial cells in an AMPK-dependent mechanism, without interfering with its cytotoxicity in cancer cells.PMID:37247463 | DOI:10.1016/j.biopha.2023.114907 (Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie)
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - May 29, 2023 Category: Drugs & Pharmacology Authors: Mohamed S Dabour Ibrahim Y Abdelgawad Marianne K O Grant Engie S El-Sawaf Beshay N Zordoky Source Type: research
Canagliflozin impairs T cell effector function via metabolic suppression in autoimmunity
Cell Metab. 2023 May 17:S1550-4131(23)00178-X. doi: 10.1016/j.cmet.2023.05.001. Online ahead of print.ABSTRACTAugmented T cell function leading to host damage in autoimmunity is supported by metabolic dysregulation, making targeting immunometabolism an attractive therapeutic avenue. Canagliflozin, a type 2 diabetes drug, is a sodium glucose co-transporter 2 (SGLT2) inhibitor with known off-target effects on glutamate dehydrogenase and complex I. However, the effects of SGLT2 inhibitors on human T cell function have not been extensively explored. Here, we show that canagliflozin-treated T cells are compromised in their abil...
Source: Cell Metabolism - May 25, 2023 Category: Cytology Authors: Benjamin J Jenkins Julianna Blagih Fernando M Ponce-Garcia Mary Canavan Nancy Gudgeon Simon Eastham David Hill Megan M Hanlon Eric H Ma Emma L Bishop April Rees James G Cronin Elizabeth C Jury Sarah K Dimeloe Douglas J Veale Catherine A Thornton Karen H V Source Type: research
Canagliflozin impairs T cell effector function via metabolic suppression in autoimmunity
Cell Metab. 2023 May 17:S1550-4131(23)00178-X. doi: 10.1016/j.cmet.2023.05.001. Online ahead of print.ABSTRACTAugmented T cell function leading to host damage in autoimmunity is supported by metabolic dysregulation, making targeting immunometabolism an attractive therapeutic avenue. Canagliflozin, a type 2 diabetes drug, is a sodium glucose co-transporter 2 (SGLT2) inhibitor with known off-target effects on glutamate dehydrogenase and complex I. However, the effects of SGLT2 inhibitors on human T cell function have not been extensively explored. Here, we show that canagliflozin-treated T cells are compromised in their abil...
Source: Cell Metabolism - May 25, 2023 Category: Cytology Authors: Benjamin J Jenkins Julianna Blagih Fernando M Ponce-Garcia Mary Canavan Nancy Gudgeon Simon Eastham David Hill Megan M Hanlon Eric H Ma Emma L Bishop April Rees James G Cronin Elizabeth C Jury Sarah K Dimeloe Douglas J Veale Catherine A Thornton Karen H V Source Type: research
Canagliflozin impairs T cell effector function via metabolic suppression in autoimmunity
Cell Metab. 2023 May 17:S1550-4131(23)00178-X. doi: 10.1016/j.cmet.2023.05.001. Online ahead of print.ABSTRACTAugmented T cell function leading to host damage in autoimmunity is supported by metabolic dysregulation, making targeting immunometabolism an attractive therapeutic avenue. Canagliflozin, a type 2 diabetes drug, is a sodium glucose co-transporter 2 (SGLT2) inhibitor with known off-target effects on glutamate dehydrogenase and complex I. However, the effects of SGLT2 inhibitors on human T cell function have not been extensively explored. Here, we show that canagliflozin-treated T cells are compromised in their abil...
Source: Cell Metabolism - May 25, 2023 Category: Cytology Authors: Benjamin J Jenkins Julianna Blagih Fernando M Ponce-Garcia Mary Canavan Nancy Gudgeon Simon Eastham David Hill Megan M Hanlon Eric H Ma Emma L Bishop April Rees James G Cronin Elizabeth C Jury Sarah K Dimeloe Douglas J Veale Catherine A Thornton Karen H V Source Type: research
Canagliflozin impairs T cell effector function via metabolic suppression in autoimmunity
Cell Metab. 2023 May 17:S1550-4131(23)00178-X. doi: 10.1016/j.cmet.2023.05.001. Online ahead of print.ABSTRACTAugmented T cell function leading to host damage in autoimmunity is supported by metabolic dysregulation, making targeting immunometabolism an attractive therapeutic avenue. Canagliflozin, a type 2 diabetes drug, is a sodium glucose co-transporter 2 (SGLT2) inhibitor with known off-target effects on glutamate dehydrogenase and complex I. However, the effects of SGLT2 inhibitors on human T cell function have not been extensively explored. Here, we show that canagliflozin-treated T cells are compromised in their abil...
Source: Cell Metabolism - May 25, 2023 Category: Cytology Authors: Benjamin J Jenkins Julianna Blagih Fernando M Ponce-Garcia Mary Canavan Nancy Gudgeon Simon Eastham David Hill Megan M Hanlon Eric H Ma Emma L Bishop April Rees James G Cronin Elizabeth C Jury Sarah K Dimeloe Douglas J Veale Catherine A Thornton Karen H V Source Type: research
Canagliflozin impairs T cell effector function via metabolic suppression in autoimmunity
Cell Metab. 2023 May 17:S1550-4131(23)00178-X. doi: 10.1016/j.cmet.2023.05.001. Online ahead of print.ABSTRACTAugmented T cell function leading to host damage in autoimmunity is supported by metabolic dysregulation, making targeting immunometabolism an attractive therapeutic avenue. Canagliflozin, a type 2 diabetes drug, is a sodium glucose co-transporter 2 (SGLT2) inhibitor with known off-target effects on glutamate dehydrogenase and complex I. However, the effects of SGLT2 inhibitors on human T cell function have not been extensively explored. Here, we show that canagliflozin-treated T cells are compromised in their abil...
Source: Cell Metabolism - May 25, 2023 Category: Cytology Authors: Benjamin J Jenkins Julianna Blagih Fernando M Ponce-Garcia Mary Canavan Nancy Gudgeon Simon Eastham David Hill Megan M Hanlon Eric H Ma Emma L Bishop April Rees James G Cronin Elizabeth C Jury Sarah K Dimeloe Douglas J Veale Catherine A Thornton Karen H V Source Type: research
Canagliflozin impairs T cell effector function via metabolic suppression in autoimmunity
Cell Metab. 2023 May 17:S1550-4131(23)00178-X. doi: 10.1016/j.cmet.2023.05.001. Online ahead of print.ABSTRACTAugmented T cell function leading to host damage in autoimmunity is supported by metabolic dysregulation, making targeting immunometabolism an attractive therapeutic avenue. Canagliflozin, a type 2 diabetes drug, is a sodium glucose co-transporter 2 (SGLT2) inhibitor with known off-target effects on glutamate dehydrogenase and complex I. However, the effects of SGLT2 inhibitors on human T cell function have not been extensively explored. Here, we show that canagliflozin-treated T cells are compromised in their abil...
Source: Cell Metabolism - May 25, 2023 Category: Cytology Authors: Benjamin J Jenkins Julianna Blagih Fernando M Ponce-Garcia Mary Canavan Nancy Gudgeon Simon Eastham David Hill Megan M Hanlon Eric H Ma Emma L Bishop April Rees James G Cronin Elizabeth C Jury Sarah K Dimeloe Douglas J Veale Catherine A Thornton Karen H V Source Type: research
Canagliflozin on top of dual renin-angiotensin system blockade in a woman with partial acquired lipodystrophy, type 2 diabetes and severely proteinuric chronic kidney disease: a case report
Sodium glucose cotransporter 2 inhibitors have proven strong efficacy in reducing end-stage renal disease in patients with type 2 diabetes. We are presenting here the case of a 40-year-old woman with acquired partial lipodystrophy, type 2 diabetes and essential hypertension complicated by chronic kidney disease and proteinuria in the nephrotic range. She first came to our attention in 2012; estimated glomerular filtration rate (eGFR) was 41.5 ml/min/1.73 m2 and total proteinuria was 375 mg/24h; she was treated with dual renin angiotensin system blocking. Proteinuria significantly increased during the following years, reach...
Source: Frontiers in Endocrinology - May 19, 2023 Category: Endocrinology Source Type: research
Racial Differences in Quality of Life in Patients With Heart Failure Treated With Sodium-Glucose Cotransporter 2 Inhibitors: A Patient-Level Meta-Analysis of the CHIEF-HF, DEFINE-HF, and PRESERVED-HF Trials
CONCLUSIONS: Treatment with an SGLT2i resulted in consistent and significant improvements in health status for both Black and White patients with heart failure.PMID:37191040 | DOI:10.1161/CIRCULATIONAHA.122.063263 (Source: Circulation)
Source: Circulation - May 16, 2023 Category: Cardiology Authors: Kashvi Gupta John A Spertus Mary Birmingham Kensey L Gosch Mansoor Husain Dalane W Kitzman Bertram Pitt Sanjiv J Shah James L Januzzi Ildiko Lingvay Javed Butler Mikhail Kosiborod David E Lanfear Source Type: research
Racial Differences in Quality of Life in Patients With Heart Failure Treated With Sodium-Glucose Cotransporter 2 Inhibitors: A Patient-Level Meta-Analysis of the CHIEF-HF, DEFINE-HF, and PRESERVED-HF Trials
CONCLUSIONS: Treatment with an SGLT2i resulted in consistent and significant improvements in health status for both Black and White patients with heart failure.PMID:37191040 | DOI:10.1161/CIRCULATIONAHA.122.063263 (Source: Circulation)
Source: Circulation - May 16, 2023 Category: Cardiology Authors: Kashvi Gupta John A Spertus Mary Birmingham Kensey L Gosch Mansoor Husain Dalane W Kitzman Bertram Pitt Sanjiv J Shah James L Januzzi Ildiko Lingvay Javed Butler Mikhail Kosiborod David E Lanfear Source Type: research
Canagliflozin alleviates high glucose-induced peritoneal fibrosis via HIF-1 α inhibition
In conclusion, we showed that Canagliflozin could improve peritoneal fibrosis and function by ameliorating peritoneal hypoxia and inhibiting the Hif-1α/TGF-β/p-Smad3 signaling pathway, providing theoretical support for the clinical use of SGLT2 inhibitors in patients on peritoneal dialysis. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - May 11, 2023 Category: Drugs & Pharmacology Source Type: research
